000155698 001__ 155698
000155698 005__ 20230915092337.0
000155698 0247_ $$2doi$$a10.1089/hum.2020.321
000155698 0247_ $$2pmid$$apmid:33752467
000155698 0247_ $$2ISSN$$a1043-0342
000155698 0247_ $$2ISSN$$a1557-7422
000155698 0247_ $$2altmetric$$aaltmetric:102569481
000155698 037__ $$aDZNE-2021-00866
000155698 041__ $$aEnglish
000155698 082__ $$a610
000155698 1001_ $$0P:(DE-2719)2810390$$aVölkner, Manuela$$b0$$eFirst author$$udzne
000155698 245__ $$aOptimized Adeno-Associated Virus Vectors for Efficient Transduction of Human Retinal Organoids.
000155698 260__ $$aNew York, NY$$bLiebert$$c2021
000155698 3367_ $$2DRIVER$$aarticle
000155698 3367_ $$2DataCite$$aOutput Types/Journal article
000155698 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1630578356_2001
000155698 3367_ $$2BibTeX$$aARTICLE
000155698 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000155698 3367_ $$00$$2EndNote$$aJournal Article
000155698 520__ $$aThe most widely used vectors for gene delivery in the retina are recombinant adeno-associated virus (rAAV) vectors. They have proven to be safe and effective in retinal gene therapy studies aimed to treat inherited retinal dystrophies, although with various limitations in transduction efficiency. Novel variants with modified capsid sequences have been engineered to improve transduction and overcome limitations of naturally occurring variants. Although preclinical evaluation of rAAV vectors based on such novel capsids is mostly done in animal models, the use of human induced pluripotent stem cell (hiPSC)-derived organoids offers an accessible and abundant human testing platform for rAAV evaluation. In this study, we tested the novel capsids, AAV9.GL and AAV9.NN, for their tropism and transduction efficiency in hiPSC-derived human retinal organoids (HROs) with all major neuronal and glial cell types in a laminated structure. These variants are based on the AAV9 capsid and were engineered to display specific surface-exposed peptide sequences, previously shown to improve the retinal transduction properties in the context of AAV2. To this end, HROs were transduced with increasing concentrations of rAAV9, rAAV9.GL, or rAAV9.NN carrying a self-complementary genome with a cytomegalovirus-enhanced green fluorescent protein (eGFP) cassette and were monitored for eGFP expression. The rAAV vectors transduced HROs in a dose-dependent manner, with rAAV9.NN achieving the highest efficiency and fastest onset kinetics, leading to detectable eGFP signals in photoreceptors, some interneurons, and Müller glia already at 2 days post-transduction. The potency-enhancing effect of the NN peptide insert was replicated when using the corresponding AAV2-based version (rAAV2.NN). Taken together, we report the application of an HRO system for screening novel AAV vectors and introduce novel vector candidates with enhanced transduction efficiency for human retinal cells.
000155698 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000155698 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000155698 650_7 $$2Other$$aadeno-associated virus
000155698 650_7 $$2Other$$aengineered AAV vector
000155698 650_7 $$2Other$$ahuman retinal organoids
000155698 650_2 $$2MeSH$$aAnimals
000155698 650_2 $$2MeSH$$aDependovirus: genetics
000155698 650_2 $$2MeSH$$aGene Transfer Techniques
000155698 650_2 $$2MeSH$$aGenetic Vectors: genetics
000155698 650_2 $$2MeSH$$aGreen Fluorescent Proteins: genetics
000155698 650_2 $$2MeSH$$aHumans
000155698 650_2 $$2MeSH$$aInduced Pluripotent Stem Cells
000155698 650_2 $$2MeSH$$aOrganoids
000155698 650_2 $$2MeSH$$aRetina
000155698 650_2 $$2MeSH$$aTransduction, Genetic
000155698 7001_ $$aPavlou, Marina$$b1
000155698 7001_ $$aBüning, Hildegard$$b2
000155698 7001_ $$0P:(DE-HGF)0$$aMichalakis, Stylianos$$b3
000155698 7001_ $$0P:(DE-2719)2000041$$aKarl, Mike Oliver$$b4$$eLast author$$udzne
000155698 773__ $$0PERI:(DE-600)1498064-2$$a10.1089/hum.2020.321$$gVol. 32, no. 13-14, p. 694 - 706$$n13-14$$p694 - 706$$tHuman gene therapy$$v32$$x1557-7422$$y2021
000155698 909CO $$ooai:pub.dzne.de:155698$$pVDB
000155698 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810390$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000155698 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000041$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000155698 9130_ $$0G:(DE-HGF)POF3-342$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vDisease Mechanisms and Model Systems$$x0
000155698 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000155698 9141_ $$y2021
000155698 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-30
000155698 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-01-30
000155698 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-30
000155698 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-24$$wger
000155698 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bHUM GENE THER : 2021$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-24
000155698 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-24
000155698 9201_ $$0I:(DE-2719)1710004$$kAG Karl$$lRetinal Regeneration and Degeneration$$x0
000155698 980__ $$ajournal
000155698 980__ $$aVDB
000155698 980__ $$aI:(DE-2719)1710004
000155698 980__ $$aUNRESTRICTED